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Abstract
Background: Asthma is associated with airway hyperresponsiveness and enhanced T-cell number/
activity on one hand and increased levels of exhaled nitric oxide (NO) with expression of inducible
NO synthase (iNOS) on the other hand. These findings are in paradox, as NO also relaxes airway
smooth muscle and has immunosuppressive properties. The exact role of the endothelial NOS
(eNOS) isoform in asthma is still unknown. We hypothezised that a delicate regulation in the
production of NO and its bioactive forms by eNOS might be the key to the pathogenesis of asthma.
Methods: The contribution of eNOS on the development of asthmatic features was examined.
We used transgenic mice that overexpress eNOS and measured characteristic features of allergic
asthma after sensitisation and challenge of these mice with the allergen ovalbumin.
Results: eNOS overexpression resulted in both increased eNOS activity and NO production in
the lungs. Isolated thoracic lymph nodes cells from eNOS overexpressing mice that have been
sensitized and challenged with ovalbumin produced significantly less of the cytokines IFN-γ, IL-5 and
IL-10. No difference in serum IgE levels could be found. Further, there was a 50% reduction in the
number of lymphocytes and eosinophils in the lung lavage fluid of these animals. Finally, airway
hyperresponsiveness to methacholine was abolished in eNOS overexpressing mice.
Conclusion:  These findings demonstrate that eNOS overexpression attenuates both airway
inflammation and airway hyperresponsiveness in a model of allergic asthma. We suggest that a
delicate balance in the production of bioactive forms of NO derived from eNOS might be essential
in the pathophysiology of asthma.
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Background
Asthma is a chronic inflammatory disease of the airways
characterized by airway obstruction, epithelial damage
and airway hyperresponsiveness [1,2]. The increased air-
way responsiveness is believed to be the result of airway
inflammation as well as epithelial damage [3-5]. There is
increasing evidence that activated T lymphocytes modu-
late the pathogenesis of asthma [6,7]. Specifically,
increased numbers of CD4+ T cells (Th2) have been found
in the bronchial mucosa of asthmatic patients, with the
consequent elevated levels of interleukin-5 (IL-5) and IL-
10 [8-10]. Moreover, interferon-γ (IFN-γ) secreting T cells
(Th1) were increased in bronchoalveolar lavage (BAL)
fluid of asthmatic patients [11,12] and it has been
reported that these T cells can induce airway inflamma-
tion with neutrophilic inflammation [13,14]. Therefore,
both Th1 and Th2 cells are important in airway inflamma-
tion and asthma [15]. In addition, inflammatory cells like
eosinophils, macrophages and neutrophils are capable of
releasing cytokines, proteases, reactive oxygen species and
lipid mediators that contribute to the pathogenesis of
asthma and the development of airway hyperresponsive-
ness [3-5,16-18].
Nitric oxide (NO) regulates many physiological processes
[19]. NO itself has a short half-life (1–5 s) because of its
reactivity with various biological compounds. On one
hand NO might react with reactive oxygen species result-
ing in nitrosative stress; on the other hand it might mod-
ificate cysteine sulphurs to form S-nitrosothiols [20], of
which S-nitrosoglutathione represents a major source of
bronchodilatory NO activity [21] NO is synthesized from
L-arginine by the enzyme NO synthase (NOS), which
exists in three distinct isoforms: constitutive neural NOS
(nNOS), inducible NOS (iNOS) and constitutive
endothelial or epithelial NOS (eNOS). The isoforms are
products of distinct genes located on different human
chromosomes, each with a characteristic pattern of tissue-
specific expression. NO produced by cNOS acts as a sig-
nalling molecule in several processes, including regula-
tion of vascular and airway smooth muscle tone [19,22].
The role of this calcium-dependent isoform in the airways
has been previously investigated. Incubation of NOS
inhibitors on the mucosal side of the guinea pig trachea
induced an increased contractile response to histamine
and cholinergic agonists [23]. Moreover, a NO deficiency
in the airways contributes to the development of airway
hyperresponsiveness in animal models for asthma, i.e.
guinea pigs with a viral respiratory tract infection [24] and
ovalbumin-sensitized and challenged guinea pigs [25,26].
Inhalation of exogenous NO causes bronchodilation in
asthmatic patients [27] and inhibition of NO production
by NO synthase inhibitors increases airway responsive-
ness in patients with mild asthma [28,29]. The calcium-
independent iNOS is induced in a wide variety of cell
types by several cytokines. NO production by iNOS is sev-
eral times higher than by cNOS [30]. In the airway epithe-
lium of human asthmatics, increased expression of iNOS
has been found [30,31] and high levels of NO produced
by this NOS isoform is thought to reflect the increased
exhaled NO levels found in asthmatic patients [32,33].
Therefore, it has been suggested that NO produced by
iNOS is a marker of inflammation.
Several studies have shown the importance of the differ-
ent NOS isoforms in asthma, either by using selective
NOS inhibitors or by using mouse strains with deletions
in one of the NOS genes. However, no studies have been
performed to investigate the effects of overexpression of
one of the NOS isoforms on the development of asth-
matic features. Furthermore, although the importance of
iNOS in asthma is well established [30,34], the precise
role of eNOS is still unknown. Interestingly, recent studies
suggest that eNOS gene polymorphisms are implicated in
asthma [35-38]. In the presence of epithelial dysfunction,
these polymorphisms may have clinical significance [39].
In the present study, we examined the contribution of
eNOS on the development of asthmatic features. We used
transgenic mice that overexpress eNOS and measured
characteristic features of allergic asthma after sensitisation
and challenge of these mice with the allergen ovalbumin.
We found that eNOS overexpression prevents the devel-
opment of airway hyperresponsiveness. Furthermore,
there was a reduction in the number of inflammatory
cells, especially eosinophils, in the lungs and an attenu-
ated production of cytokines by lymph node cells in these
animals. We conclude that eNOS overexpression result in
attenuation of both airway hyperresponsiveness and air-
way inflammation.
Methods
Generation of eNOS transgenic mice
A genomic clone has been isolated from a home-made
cosmid library [40]. It comprises the complete, unmodi-
fied gene encoding endothelial NO synthase (eNOS,
NOS3) plus its natural flanking sequences. These consist
of ~ 6 kb of the 5' sequence, including the natural promo-
tor, and ~ 3 kb of the 3' sequence. Vector sequences were
removed by restriction endonuclease digestion and DNA
was dissolved in micro-injection buffer (10 mmol/L Tris-
HCl, pH 7.5; 0.1 mmol/L EDTA) at a concentration of 2
µg/ml. The DNA was micro-injected into fertilized oocytes
from FVB mice. These oocytes were transferred into the
oviducts of pseudopregnant foster females. Mice used in
the present study were backcrossed for at least 5 genera-
tions onto a C57BL/6 background (>96% C57BL/6), the
controls (WT) for the eNOS overexpressing mice (eNOS).
The mice were housed in macrolon cages and provided
with food and water ad libitum. All animal experimentsRespiratory Research 2006, 7:58 http://respiratory-research.com/content/7/1/58
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were performed in compliance with the Guidelines of the
Ethical Committee on the Use of Laboratory Animals of
The University Utrecht and Erasmus University Rotter-
dam.
eNOS activity measurements
eNOS activity was measured in lung tissue by the L-
arginine to L-citrulline conversion assay using a nitric
oxide synthase assay kit (Calbiochem, La Jolla, CA, USA;
cat. no. 482700) according to the manufacturer's instruc-
tions.
Western blot analysis of eNOS
Lung tissue isolated from control or eNOS overexpressing
mice were homogenized in 1 ml of 50 mM Tris-HCl
buffer, pH 7.8, containing 150 mM NaCl, 1 mM EDTA, 1
mM sodium vanadate, 1% NP-40, 1 mM phenylmethyl-
sulfonyl fluoride (PMSF). The samples were transferred to
eppendorf tubes and centrifuged at high speed in a micro-
centrifuge for 10 minutes at 4°C to remove insoluble
material. Protein content was determined using the
method of Bradford [41] with BSA as standard. Equal
amounts of protein were added to a 0.1 M Tris buffer con-
taining 50 µM dithiothreitol, 0.01% bromophenol blue,
1% sodium dodecyl sulfate (SDS) and 10% glycerol and
boiled for 5 minutes. Proteins (30 µg/lane) were electro-
phoresed under reducing, denaturing conditions in 7.5%
SDS polyacrylamide gel, transferred to nitrocellulose
paper and probed with an antibody against humans
eNOS (Santa Cruz Biotechnology, Inc., Santa Cruz, Cali-
fornia, USA) or with an antibody against the phosphor-
ylated site of eNOS (P-eNOS, Cell Signaling Technology,
Beverly, MA, USA). Antibody binding was detected using
an amplified alkaline phosphatase immuno blot kit (Bio-
rad Laboratories, Hercules, California, USA) according to
the manufacturer's recommendation.
Sensitization and challenge
All mice were sensitized to ovalbumin (OVA; chicken egg
albumin, grade V, Sigma, St. Louis, MO, USA). Active sen-
sitization was performed by 2 intraperitoneal injections of
0.1 ml alum-precipitated antigen, comprising 10 µg OVA
absorbed onto 2.25 mg alum (AlumImject; Pierce, Rock-
ford, IL, USA) on day 0 and 14. Four weeks after the last
injection, the mice were exposed either to an OVA (10
mg/ml in pyrogen-free saline, OVA group) or control
solution (saline, SAL group) aerosol challenge for 20 min-
utes once daily on day 42, 45 and 48. The aerosol was per-
formed in a plexiglass exposure chamber (5 L) coupled to
a Pari LC Star nebulizer (PARI Respiratory Equipment,
Richmond, VA, USA; particle size 2.5–3.1 µm) driven by
compressed air at a flow rate of 6 L/min. Aerosol was given
in groups composed of 6 animals.
Measurement of airway responsiveness in vivo
Airway responsiveness was measured in conscious, unre-
strained mice 24 hours after the last aerosol exposure
using barometric whole-body plethysmography by
recording respiratory pressure curves (Buxco; EMKA Tech-
nologies, Paris, France) in response to inhaled metha-
choline (acetyl-β-methyl-choline chloride, Sigma).
Airway responsiveness was expressed in enhanced pause
(Penh), which is a measure of bronchoconstriction, as
described in detail previously [42]. Briefly, mice were
placed in a whole-body chamber, and basal readings were
obtained and averaged for 3 min. Aerosolized saline, fol-
lowed by increasing doubling concentrations (1.56 – 25
mg/ml saline) of methacholine, were nebulized for 3 min,
and readings were taken and averaged for 3 min after each
nebulization.
Analysis of cellular composition of bronchoalveolar lavage 
(BAL) fluid
Following airway responsiveness measurements, mice
received a lethal dose of pentobarbitone sodium (Euthe-
sate® 0.6 mg/kg body weight, intraperitoneally). The tra-
chea was trimmed free of connective tissue and a small
incision was made to insert a cannula in the trachea. Via
this cannula, the lungs were filled with 1 ml aliquots of
pyrogen free saline (37°C) supplemented with aprotinin
(2 µg/ml, Sigma). Fluid was collected in plastic tubes on
ice. This procedure was repeated 3 times with aliquots of
pyrogen free saline and fluid was collected in a separate
plastic tube on ice and cell suspensions recovered from
each animal were pooled. BAL cells were centrifuged (400
× g, 4°C, 5 min) and supernatant from 1 ml aliquots were
collected and stored (-30°C) until cytokines and NO were
measured by ELISA and NO analyzer. The pellets from the
first ml and 3 ml aliquots were pooled and resuspended
in 150 µl PBS. The total number of cells in the BAL fluid
was determined using a Bürker-Türk bright-line counting
chamber (Karl Hecht Assistant KG, Sondheim/Rohm,
Germany). For differential BAL fluid cell counts, cytospin
preparations were made and stained with Diff-Quik
(Dade AG, Düdingen, Switzerland). Per cytospin, 200
cells were counted and differentiated into alveolar macro-
phages, eosinophils, lymphocytes and neutrophils by
light microscopical observation under oil immersion.
Serum levels of total IgE
Blood samples were obtained from the mice via a cardiac
puncture, left at room temperature for two hours and sub-
sequently centrifuged for 10 min at 20,000 × g. Serum was
collected and samples were kept at -20°C until analysis.
Total IgE was measured using an ELISA method. Briefly,
microtiter plates (Nunc A/S, Roskilde, Denmark) were
coated overnight at 4°C with 2 µg/ml rat anti-mouse IgE
(clone EM95) diluted in phosphate-buffered saline (PBS).
The next day, the ELISA was performed at room tempera-Respiratory Research 2006, 7:58 http://respiratory-research.com/content/7/1/58
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ture. After blocking with ELISA buffer (PBS containing
0.5% bovine serum albumin (Sigma), 2 mM EDTA, 136.9
mM NaCl, 50 mM Tris, 0.05% Tween-20 (Merck, White-
house Station, NJ, USA) pH 7.2) for 1 hour, serum sam-
ples diluted in ELISA buffer, were added for 2 hours.
Thereafter, plates were incubated with 1 µg/ml second
biotinylated antibody (Biotin anti-mouse IgE, PharMin-
gen, San Diego, CA, USA) diluted in ELISA buffer for 1.5
hours. After washing, streptavidin-peroxidase (0.1 µg/ml,
CLB, Amsterdam, The Netherlands) was added and incu-
bation was performed for 1 hour. Color development was
performed with o-phenylenediamine-dichloride substrate
(0.4 mg/ml; Sigma) and 0.04% H2O2 in PBS and stopped
by adding 4 M H2SO4. The optical density was read at 492
nm, using a Benchmark microplate reader (Bio-Rad Labo-
ratories, Hercules, CA, USA).
Determination of cytokine production by OVA-
restimulated thoracic lymph nodes cells in vitro
Cytokine production by antigen-stimulated T cells derived
from thoracic lymph nodes (TLN) was determined as
described previously [43]. Briefly, TLN draining the lungs
were removed, transferred to cold sterile PBS and filtered
through a 70- µm nylon cell strainer (Becton Dickinson
Labware, Franklin Lakes, NJ) with 10 ml RPMI 1640 to
obtain a single-cell suspension. The lymph node cells
were washed and resuspended in culture medium (RPMI
1640 containing 10% FCS, 1% glutamax I, and gen-
tamicin (all from Life Technologies, Gaithersburg, MD,
USA) and 50 mM -mercaptoethanol (Sigma). Cells were
cultured in flat bottom 96-well plates (Greiner Bio-One
GmbH, Kremsmuenster, Austria) at a concentration of 1 ×
106 cells per ml in a volume of 200 µl. The cells were cul-
tured for 5 days (37°C with 5% CO2 in humidified air)
with culture medium or OVA (10 µg/ml). Each in vitro
stimulation was performed in triplicate. After 5 days of
culture, the supernatant was harvested, pooled per stimu-
lation, and stored at -20°C until cytokine levels were
determined by ELISA. The IFN-γ, IL-5 and IL-10 ELISAs
were performed according to the manufacturer's instruc-
tions (PharMingen, San Diego, CA, USA).
Determination of cytokine levels in BAL fluid
Cytokine levels were determined in supernatant of the
first ml of the lavage fluid by ELISA (see above). IFN-γ and
IL-10 levels in BAL fluid were below detection limit.
Measurement of NO in BAL fluid
NO levels were determined in the BAL fluid. Therefore,
the first ml of the lavage fluid was centrifuged and the
supernatant was kept at -20°C until analysis. The remain-
ing pellet was resuspended in the recovered lavage fluid
and used to determine total and differential cell numbers
(see above). Both nitrite, nitrate and S-nitrosothiol levels
(NOx) in BAL fluid were determined as stable and repre-
sentative breakdown products of NO [44]. Therefore,
samples of 25 µl of BAL fluid were injected into a gas strip-
ping apparatus containing 2 ml of a 1% solution of vana-
dium (III) chloride in hydrochloric acid at 90°C which
was connected to a Sievers 280i NO analyser (Boulder,
CO, USA). NO was measured according to the instruc-
tions of the manufacturer (Sievers Nitric Oxide Analyzer
NO A280, Operational Service Manual, Boulder, CO,
USA; Sievers Instruments I 1996) [45]. The sensitivity of
the NO analyser is < 10 pmol/ml, with a linearity of 4
orders of magnitude. Calibrations were made according to
the manufacturer's instructions with standard solutions of
sodium nitrate and sodium nitrate (Sigma), respectively
[46].
Statistical analysis
All data are expressed as mean ± SEM. Differences in
eNOS activity, total NO levels in BAL fluid, total and dif-
ferential cell numbers in BAL fluid, cytokine production
by thoracic lymph nodes and IL-5 levels in BAL fluid were
tested using the Student's t-test (unpaired). Differences
between groups after aerosolized methacholine were
tested by a general linear model of repeated measure-
ments followed by post-hoc comparison between groups.
Data were log transformed before analysis to equalize var-
iances in all groups. Also, the Student's t-test (unpaired)
was used to determine statistical differences between
groups at 25 mg/ml methacholine concentration. All p-
values <0.05 were considered to reflect a statistically sig-
nificant difference.
Immunoblotting of lung tissue from WT and eNOS mice Figure 1
Immunoblotting of lung tissue from WT and eNOS mice. 
Increased expression of both eNOS (α-eNOS) and phospho-
rylated eNOS (α-P-eNOS) was found in eNOS mice com-
pared to WT mice. Experiments have been performed at 
least three times in which similar results were obtained.
Į-eNOS Į-P-eNOS
WT eNOS WT eNOSRespiratory Research 2006, 7:58 http://respiratory-research.com/content/7/1/58
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Results
Increased eNOS overexpression and eNOS activity in lungs 
of eNOS overexpressing mice
The presence of eNOS protein in lung tissue was detected
by immunoblotting using two different antibodies. First,
using an antibody against human eNOS (α-eNOS), a faint
band was observed in lung tissue from WT animals,
whereas a much more prominent band could be detected
with lung tissue derived from eNOS mice (Fig 1A). Sec-
ondly, since the enzymatic activity of eNOS is tightly reg-
ulated by different mechanisms, such as the
phosphorylation on Ser1179 by the serine/threonine pro-
tein kinase Akt [47,48], we also used an antibody against
phosphorylated eNOS (α-P-eNOS). As shown in figure 1,
endogenous mouse P-eNOS was not detectable in the WT
mice, whereas P-eNOS was present in lungs from eNOS
mice.
We also measured eNOS activity in lungs from WT mice
and eNOS overexpressing mice using the L-arginine to L-
citrulline conversion assay. The eNOS mice showed a 25-
fold increased activity compared to WT mice (Fig 2A). Fur-
thermore, eNOS mice produce more NO in the lungs,
since nitrite and nitrate (NOx) levels in BAL fluid were
increased by 90% in eNOS mice (SAL/eNOS) compared
to WT mice (SAL/WT, Fig 2B). From these data we con-
clude that eNOS is indeed overexpressed in eNOS mice
and that eNOS activity is increased in these mice.
eNOS is localized in endothelium
The localization of eNOS expressed by the transgenic mice
was evaluated by immunohistochemistry studies in lung
sections. While the alveolar septa of control mice were
only faintly stained, these show a strong signal in trans-
genic mice (Fig 3A and 3B, respectively). The staining
appeared to be present in the interior parts of the alveolar
septa, which is clearly visible at a higher magnification
(Fig 3C), in which immuno-positive capillaries in the
septa can be discriminated while the type I cells that line
the alveolar surfaces are not stained. Bronchioles are not
stained (Fig 3D).
eNOS overexpression suppresses the influx of 
inflammatory cells into the lungs
To study the effects of eNOS overexpression on the influx
of inflammatory cells into the lungs after OVA challenge,
total and differential cell numbers in the BAL fluid 24
hours after OVA challenge were determined. Total cell
numbers of SAL/WT and SAL/eNOS mice were 13.4 ± 1.2
× 104 and 25.3 ± 4.7 × 104, respectively (p < 0.05). The
number of alveolar macrophages was more than two
times higher in SAL/eNOS mice compared to SAL/WT
mice (p < 0.01, Fig 4B). Also a small, but not significant
(NS, p = 0.09) increase in the number of lymphocytes
could be observed in SAL/eNOS mice compared to SAL/
WT mice (Fig 4C). Eosinophils (Fig 4D) and neutrophils
(data not shown) were not present in BAL fluid of both
SAL/WT and SAL/eNOS mice. Aerosol OVA exposure
increased the total cell numbers to 695 ± 48 × 104 in OVA/
WT mice and to 366 ± 32 × 104 in OVA/eNOS mice. There-
fore, there was a 47% reduction (p < 0.001) in total cell
numbers in OVA/eNOS compared to OVA/WT mice (Fig
4A). The increase in total cell numbers after OVA chal-
lenge was mainly due to an increase in the number of eosi-
nophils (80% of total cell population in OVA/WT mice).
In OVA/eNOS mice, there was a 46% reduction in the
number of eosinophils compared to OVA/WT mice (p <
0.001, Fig 4D). Furthermore, eNOS overexpression
reduced the increase in the number of lymphocytes (54%,
p < 0.05, Fig 4C) after OVA challenge. However, no differ-
(A) eNOS activity in lung homogenates from WT (white bars) and eNOS (hatched bars) mice measured by using the arginine  to citrulline conversion assay and (B) NOx levels measured in BAL fluid of WT mice (white bars) and eNOS mice (hatched  bars) Figure 2
(A) eNOS activity in lung homogenates from WT (white bars) and eNOS (hatched bars) mice measured by using the arginine 
to citrulline conversion assay and (B) NOx levels measured in BAL fluid of WT mice (white bars) and eNOS mice (hatched 
bars). Increased eNOS activity was observed in eNOS mice compared to WT mice. NOx levels were higher in eNOS mice 
compared to WT mice. eNOS activity is expressed as mean ± SEM arbitrary units, n = 6. NOx data are presented as mean ± 
SEM, n = 6. ### p < 0.001 compared to WT mice.
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Immunohistochemistry of sections from lung tissue with antibodies directed against human eNOS Figure 3
Immunohistochemistry of sections from lung tissue with antibodies directed against human eNOS. A) Control mice: Only a 
faint background staining is present. B) eNOS transgenic mice: eNOS is localized in the alveolar septa in lungs. C) eNOS trans-
genic mice: eNOS is present within the septa. Arrowheads point at alveolar capillaries. No signal is seen in the type I cells lining 
the alveoli (double arrowheads). D) eNOS transgenic mice: No signal is seen in the cells from the bronchiole (Br), while the 
endothelial cells from the small vessel accompanying the bronchiole show staining (arrow). Original magnifications: 100× (A, B, 
D) and 630× (C). Experiments have been performed at least three times in which similar results were obtained.Respiratory Research 2006, 7:58 http://respiratory-research.com/content/7/1/58
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ence in the number of macrophages (Fig 4B) and neu-
trophils (data not shown) could be found in OVA/eNOS
mice compared to OVA/WT mice. From these results we
conclude that eNOS overexpression reduces the influx of
inflammatory cells, predominantly eosinophils, into the
lungs after OVA challenge.
eNOS overexpression does not affect IgE levels in serum
eNOS overexpression in SAL challenged mice had no
influence on IgE levels in serum (Fig 5A). Antigen chal-
lenge induced a significant increase in serum levels of
total IgE in both WT mice (p < 0.01) and eNOS mice (p <
0.01), compared to SAL challenged mice (Fig 5A). No dif-
ference in serum IgE levels between OVA/WT and OVA/
eNOS mice could be observed (Fig 5A). From this we con-
clude that eNOS overexpression has no effect on IgE levels
in serum both after saline and ovalbumin challenge.
eNOS overexpression suppresses cytokine production by 
thoracic lymph nodes in vitro
We next compared the cytokine profiles of TLN cells
obtained from WT and eNOS mice. eNOS overexpression
in SAL challenged mice had no influence on IFN-γ pro-
duction by TLN cells in vitro (Fig 5B). However, IL-5 pro-
Cell numbers in BAL fluid obtained 24 hours after challenge from SAL/WT mice (white bars), SAL/eNOS mice (hatched bars),  OVA/WT mice (black bars) and OVA/eNOS mice (grey bars) Figure 4
Cell numbers in BAL fluid obtained 24 hours after challenge from SAL/WT mice (white bars), SAL/eNOS mice (hatched bars), 
OVA/WT mice (black bars) and OVA/eNOS mice (grey bars). A) total cell numbers in BAL fluid. Total cell numbers are 
increased in OVA/WT mice compared to SAL/WT mice. Total cell numbers are decreased by 47% in OVA/eNOS mice com-
pared to OVA/WT mice. B) number of alveolar macrophages in BAL fluid. The number of macrophages is increased in SAL/
eNOS mice compared to SAL/WT mice. Numbers of macrophages were 4 times increased in OVA/WT mice compared to 
SAL/WT mice. No difference in macrophages was observed between OVA/eNOS and OVA/WT mice. C) number of lym-
phocytes in BAL fluid. Hardly any lymphocytes could be detected in SAL/WT and SAL/eNOS mice. A markedly increased 
number of lymphocytes were found in OVA/WT mice compared to SAL/WT mice. A 54% reduction in lymphocytes was found 
in OVA/eNOS mice compared to OVA/WT mice (p < 0.05). D) number of eosinophils in BAL fluid. No eosinophils were 
present in the BAL fluid of SAL/WT mice and SAL/eNOS mice (ND = not detectable). A dramatic increase in eosinophils was 
detected in OVA/WT mice compared to SAL/WT mice. Compared to OVA/WT, there was a 46% reduction in the increase in 
eosinophils in the BAL fluid in OVA/eNOS mice (p < 0.001). Data are presented as mean ± SEM, n = 9. * p < 0.05, ** p < 0.01, 
$$ p < 0.01, *** p < 0.001 compared to SAL/WT mice, # p < 0.05, ### p < 0.001 compared to OVA/WT mice.
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duction (Fig 5C) was completely absent in TLN cells
obtained from SAL/eNOS mice (0.41 ± 0.2 pg/ml) com-
pared to SAL/WT mice (312 ± 70 pg/ml). Furthermore,
eNOS overexpression significantly (p < 0.001) reduced in
vitro production of IL-10 by TLN (4.74 ± 1.35 pg/ml in
SAL/eNOS mice and 68.9 ± 12.1 pg/ml in SAL/WT mice;
Fig 5D). OVA challenge highly increased IFN-γ produc-
tion in WT mice (p < 0.05) compared to SAL/WT, whereas
no significant increase in IFN-γ production was observed
in cells derived from OVA/eNOS mice compared to SAL/
eNOS (Fig 5B). Interestingly, IFN-γ production was
decreased by 90% in OVA/eNOS mice compared to OVA/
WT mice. After OVA challenge, an increased production of
IL-5 and IL-10 (both p < 0.001) by TLN cells in vitro was
found in WT mice (Fig 5C + Fig 5D). In OVA/eNOS mice,
IL-5 and IL-10 production was decreased by 44% and
51%, respectively, compared to OVA/WT mice (both p <
0.01). From this we conclude that eNOS overexpression
attenuates IFN-γ, IL-5 and IL-10 production by TLN cells
in vitro after OVA challenge.
eNOS overexpression attenuates IL-5 levels in BAL fluid
Next, we measured IL-5 levels in BAL fluid. eNOS overex-
pression in SAL challenged mice had no influence on IL-5
Ovalbumin-specific IgE levels in serum and different production of cytokines by TLN cells after OVA restimulation in vitro in  SAL/WT mice (white bars), SAL/eNOS mice (hatched bars), OVA/WT mice (black bars) and OVA/eNOS mice (grey bars) Figure 5
Ovalbumin-specific IgE levels in serum and different production of cytokines by TLN cells after OVA restimulation in vitro in 
SAL/WT mice (white bars), SAL/eNOS mice (hatched bars), OVA/WT mice (black bars) and OVA/eNOS mice (grey bars). A) 
IgE levels in serum 24 hours after challenge. An increase in IgE was observed after OVA challenge. No difference between 
eNOS and the respective WT mice was detected. B) IFN-γ production by TLN. No IFN-γ was produced by TLN cells obtained 
from SAL/WT and SAL/eNOS mice. IFN-γ production was markedly increased in OVA/WT mice, but only slightly in OVA/
eNOS mice. C) IL-5 production by TLN cells. Low levels of IL-5 were found in SAL/WT mice, whereas no IL-5 production was 
found in SAL/eNOS mice. IL-5 levels were markedly increased in OVA/WT mice compared to SAL/WT mice. IL-5 production 
was decreased by 44% in OVA/eNOS mice compared to OVA/WT mice (p < 0.01). D) IL-10 production by TLN cells. Low 
levels of IL-10 were found in SAL/WT mice, whereas no IL-10 production was found in SAL/eNOS mice. IL-10 levels were 
increased in OVA/WT mice compared to SAL/WT mice. IL-10 production was decreased by 51% in OVA/eNOS mice com-
pared to OVA/WT mice (p < 0.01). Data are presented as mean ± SEM, n = 6. * p < 0.05, ** p < 0.01, *** p < 0.001, $$$ p < 
0.001 compared to SAL/WT mice, ## p < 0.01 compared to OVA/WT mice.
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levels in BAL fluid (Fig 6). IL-5 levels in BAL fluid of OVA/
WT mice were significantly increased (p < 0.05) compared
to SAL/WT. IL-5 levels in BAL fluid were significantly (p <
0.01) reduced in OVA/eNOS mice compared to OVA/WT
mice (Fig 6). We conclude that eNOS overexpression
reduces IL-5 levels in BAL fluid after OVA challenge.
eNOS overexpression prevents the development of airway 
hyperresponsiveness
To investigate the effects of eNOS overexpression on the
development of airway hyperresponsiveness, airway
responsiveness to methacholine (expressed as Penh val-
ues) 24 hours after OVA challenge was measured in unre-
strained mice in a Buxco set-up. Basal responsiveness was
slightly increased in OVA-challenged mice compared to
SAL- challenged mice (0.85 ± 0.11 vs 0.71 ± 0.06 in WT
mice and 0.85 ± 0.08 vs 0.65 ± 0.04 in eNOS mice). No
difference in airway responsiveness to methacholine
between SAL/WT mice and SAL/eNOS mice could be
observed (Fig 7). Airway responsiveness to methacholine
was significantly (p < 0.01) increased in OVA/WT mice
compared to SAL/WT mice (Fig 7). However, no statisti-
cally significant difference in airway responsiveness to
methacholine could be found between OVA/eNOS mice
and SAL/eNOS mice (p = 0.10). In OVA/eNOS mice, there
was a 35% reduction in airway responsiveness to 25 mg/
ml methacholine compared to OVA/WT mice (p < 0.05,
Fig 7). Thus, OVA/eNOS mice are less responsive to high
concentrations of methacholine compared to OVA/WT
mice.
Discussion
NO has been implicated in many physiological and
pathophysiological processes and it may play a crucial
role in airway functioning both during health and disease
[19]. In healthy situations, NO derived from cNOS seems
to be predominant, since low levels of NO produced by
cNOS controls airway smooth muscle tone [23,24,49].
During asthmatic disease however, high levels of NO
derived from the iNOS isoform are a major contributor to
the inflammatory process seen in asthma [30,34].
Several studies have shown the importance of the differ-
ent NOS isoforms in the development of asthmatic fea-
tures, such as increased airway responsiveness, airway
inflammation and increased production of several
cytokines. Xiong et al [34] again stressed the role of the
iNOS isoform in the inflammatory process in asthma. In
contrast, De Sanctis et al [50] showed that the iNOS iso-
form is not important in the development of airway
inflammation. Furthermore, Feder et al [51] showed that
a selective iNOS inhibitor had no effect on the influx of
eosinophils into the lungs of allergen-challenged mice.
Moreover, no increase in pulmonary iNOS was found in
sensitized and challenged mice. These findings suggest
that the iNOS isoform is not the only factor contributing
to airway inflammatory processes. In the present study,
we have used eNOS overexpressing mice to explore the
effects of this NOS isoform on the development of asth-
matic features in a mouse model of allergic asthma. Our
results show that eNOS plays a crucial role in both airway
hyperresponsiveness and airway inflammation.
Overexpression of eNOS in mice was confirmed by several
ways. First, immunoblot analysis showed eNOS expres-
sion in the lungs of overexpressing mice, however, this
protein was hardly found in wild type mice. Using the L-
arginine to L-citrulline conversion assay, it was demon-
strated that eNOS activity was significantly increased in
the lungs of overexpressing mice. NOx levels were more
than doubled in the bronchoalveolar lavage fluid of over-
expressing mice and immunohistochemistry indicated an
increased expression of eNOS in the lungs. These results
indicate that eNOS-derived NO has functional properties
in the lungs of these mice [52].
NO itself has a very short half-life and reacts rapidly with
many different molecules in a biological environment. S-
nitrosothiols are important molecules signaling NO bio-
activity in the airways. Low levels of S-nitrosothiols are
associated with severe asthma [53], and recently, Que et
al. [21] showed that allergic mice that cannot metabolize
S-nitrosothiols are completely protected from airway
IL-5 levels in BAL fluid in SAL/WT mice (white bars), SAL/ eNOS mice (hatched bars), OVA/WT mice (black bars) and  OVA/eNOS mice (grey bars) Figure 6
IL-5 levels in BAL fluid in SAL/WT mice (white bars), SAL/
eNOS mice (hatched bars), OVA/WT mice (black bars) and 
OVA/eNOS mice (grey bars). Low levels of IL-5 were found 
in SAL/WT and SAL/eNOS mice. IL-5 levels were increased 
in OVA/WT mice compared to SAL/WT mice. IL-5 levels 
were markedly decreased in OVA/eNOS mice compared to 
OVA/WT mice. Data are presented as mean ± SEM, n = 6. * 
p < 0.05 compared to SAL/WT mice, ## p < 0.01 compared 
to OVA/WT mice.
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hyperresponsiveness. Moreover, S-nitrosothiols repressed
the action of inhibitory κB kinase, providing a mechanism
for the anti-inflammatory properties of NO [54]. We can
speculate that overexpression of eNOS in the airways
leads to higher concentrations of NO and the consequent
higher levels of S-nitrosothiols in the lungs.
Airway inflammation is the key factor in the pathogenesis
of asthmatic disease [55]. Besides other inflammatory
cells, the eosinophil is thought to be one of the major
effector cells in asthma. In the present study we found that
eNOS overexpression reduced the influx of eosinophils
into the lungs after ovalbumin challenge by 46%. A direct
effect of NO on lung eosinophilic influx is doubtful.
Although chemical inhibition of NO activity has been
shown to suppress pulmonary eosinophilic inflammation
in mice [51,56], in NOS1, 2 and 3 KO mice no difference
in the number of lung eosinophils could be observed [50].
Eosinophil mobilisation and trafficking are largely pro-
moted by the Th2 cytokine IL-5 [57]. Ablation of the
effects of IL-5 has been accomplished with blocking anti-
IL-5 antibody, which was accompanied by a reduction in
allergen-induced eosinophilia [58-60]. We found that IL-
5 production by TLN cells in vitro is reduced by 44% in
OVA/eNOS mice. Furthermore, IL-5 was almost com-
pletely absent in the BAL fluid of these mice. The attenu-
ated IL-5 production might account for the reduced
presence of eosinophils in the lungs. Interestingly, IL-5
production by TLN cells was completely absent in SAL/
eNOS mice. Therefore, eNOS overexpression might, via
inhibition of IL-5 production, attenuate the maturation of
eosinophils in the bone marrow [51,61].
In the present study, we also found reduced levels of lym-
phocytes in the BAL fluid of OVA/eNOS mice. Although
we did not measure numbers of circulating white blood
cells, it has been reported that NO inhibits leukocyte
adhesion and migration through the endothelial cell layer
[62]. Since immunohistochemical data showed overex-
pression of eNOS predominantly in the endothelium, an
NO-induced decrease in leukocyte adhesion might, at
least partly, offer an explanation for the decreased airway
inflammation in this mouse strain. Moreover, NO attenu-
ates T cell proliferation [63,64] and, at high levels, NO can
induce T cell apoptosis through S-nitrosylation of differ-
ent target proteins [65,66].
Airway hyperresponsiveness is a well-established charac-
teristic of allergic asthma and is believed to be the result
of airway inflammation as well as epithelial damage
[23,67]. Interestingly, several studies have shown that
eNOS KO mice are hyperresponsive to inhaled bronchoc-
onstrictor agents like methacholine [49,50]. We show in
the present study that the development of airway hyperre-
sponsiveness was completely prevented in OVA/eNOS
mice at a high methacholine concentration. It is not
unlikely that this is due to the fact that only at high con-
centration of a bronchoconstricting agent, high levels of
NO are necessary to counteract this constriction. This idea
is supported by the observation that eNOS overexpression
has no effect on basal responsiveness to methacholine.
A disbalance between Th2 and Th1 lymphocytes seems to
be correlated with the development of atopic diseases
[8,17,68]. mRNA expression data in BAL cells from atopic
asthmatics showed a predominant Th2 cell like pattern
[8,10], with the consequent elevation of IL-4 and IL-5
[69]. Furthermore, Th1 cells are thought to antagonize
Th2 cell functions [7]. Previously, a role for iNOS in the
Th1/Th2 balance was proposed, since in iNOS KO mice a
suppression of allergic inflammation was found, which
was accompanied by an increased IFN-γ production by T
cells [34]. However, other studies showed that antigen-
specific Th1 cells do not protect or prevent Th2-mediated
allergic diseases, but rather may cause acute lung pathol-
ogy [14,15,70]. Furthermore, IFN-γ levels are elevated in
serum [12] and BAL fluid [11,71] of patients with asthma.
Interestingly, treatment with antibodies to IFN-γ com-
pletely abolished airway hyperresponsiveness, but had no
effect on airway eosinophilia [59]. In contrast, other stud-
ies have shown that anti-IL-5 blocks eosinophilic influx
into the lungs, although hardly any effect on airway
Airway responsiveness (expressed as Penh) to aerosolized  methacholine was measured in conscious, unrestrained mice  24 hours after challenge Figure 7
Airway responsiveness (expressed as Penh) to aerosolized 
methacholine was measured in conscious, unrestrained mice 
24 hours after challenge. Increased airway responsiveness to 
methacholine (p < 0.01) was observed in OVA/WT mice 
(black bar, n = 7) compared to SAL/WT mice (white bar, n = 
9). No effect on airway responsiveness was observed in SAL/
eNOS mice (hatched bar, n = 7). Airway hyperresponsive-
ness was abolished in OVA/eNOS mice (grey bar, n = 11) 
compared to OVA/WT mice (p < 0.05 at 25 mg/ml metha-
choline). Data are presented as mean ± SEM. # p < 0.05 com-
pared to OVA/WT mice.
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hyperresponsiveness could be observed [59,72]. In the
present study, we found attenuated levels in OVA/eNOS
mice of both the Th1 cytokine IFN-γ and the Th2
cytokines IL-5 and IL-10 compared to OVA/WT mice.
Therefore, NO derived from eNOS might be involved in
the attenuated production of both Th1 and Th2 cytokines,
resulting in diminished airway inflammation and,
although not causally related [21], this might reduce the
development of airway hyperresponsiveness. Indeed, NO
inhibits the secretion of IFN-γ by Th1 cells [32,73,74] and
IL-5 and IL-10 by Th2 cells [75] by affecting several sign-
aling molecules and transcription factors in T cells
(recently reviewed in [76]).
The role of IL-10 in asthma remains controversial. Some
studies found a higher IL-10 expression in subjects with
asthma than in control subjects [77], whereas others
found lower IL-10 levels [78]. Furthermore, although
some studies show a close relationship between IL-10 and
iNOS levels [79], no data exists showing a role for IL-10
and eNOS expression. In the present study, we demon-
strated a significantly lower IL-10 production by TLN cells
in SAL/eNOS mice and OVA/eNOS mice compared to
their respective controls. The attenuated IL-10 production
in eNOS mice might contribute to the reduced develop-
ment of asthmatic features in this asthma model.
Atopic individuals can be recognized by the presence of
allergen-specific IgE in their serum and by elevations of
the total serum IgE [6]. Indeed, we found elevated levels
of total IgE in serum after ovalbumin challenge, but we
could not observe any differences between OVA/WT and
OVA/eNOS mice. These results confirm the finding by De
Sanctis et al [50], who observed no difference between IgE
levels in several NOS isoform KO mice after challenge
with ovalbumin compared to WT mice.
Conclusion
We have shown that overexpression of the eNOS gene pre-
vents the development of airway hyperresponsiveness,
airway inflammation and the production of Th1 and Th2
cytokines in a mouse model of allergic asthma. Although
it has been assumed for many years that iNOS has a pri-
mary role in inflammatory diseases like asthma
[30,32,80], recent studies suggest an important role for
the cNOS isoforms in controlling asthmatic disease
[22,50,51,81]. Interestingly, eNOS gene polymorphisms
have been associated with atopic asthma [35,38], with
lower NO concentrations leading to persistent airway
inflammation [37]. The eNOS gene therefore seems a
promising new target for new insights and new opportu-
nities for improvements in therapy against asthmatic dis-
ease.
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